Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC
Ontology highlight
ABSTRACT:
DISEASE(S): Solid Tumor,Cervical Cancer,Gastrointestinal Cancer,Colorectal Cancer,Bladder Cancer,Pancreatic Cancer,Lung Neoplasms,Neoplasms,Carcinoma, Squamous Cell,Ovarian Cancer,Nsclc,Advanced Solid Tumor,Carcinoma, Non-small-cell Lung,Lung Diseases
PROVIDER: 2308561 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
Similar Datasets
Project description:Pharmacokinetic/pharmacodynamic (PK/PD) studies are an essential component of pre-clinical drug discovery. Current best approaches for PK/PD studies, including the analysis of novel kidney disease targeting therapeutic agents, are limited to animal models with unclear translatability to the human condition. To address this challenge, we developed a novel approach for PK/PD studies using transplanted human kidney organoids. We performed PK studies with GFB-887, an investigational new drug now in Phase 2 trials. Orally dosed GFB-887 to athymic rats that had undergone organoid transplantation resulted in measurable drug exposure in human transplanted organoids. Importantly, we established the efficacy of orally dosed GFB-887 in PD studies, where quantitative analysis showed significant protection of kidney filter cells in human organoids and endogenous rat host kidneys. This widely applicable approach demonstrates, for the first time, feasibility of using transplanted human organoids in PK/PD studies, empowering organoids to revolutionize drug discovery.
2022-06-14 | GSE165104 | GEO
Project description:This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with zimberelimab (AB122) (an anti-PD-1 antibody) in participants with advanced malignancies.
| 2280960 | ecrin-mdr-crc
Project description:This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of etrumadenant (AB928) in combination with mFOLFOX in participants with advanced metastatic gastroesophageal Cancer (GEC) or colorectal cancer (CRC).
| 2287946 | ecrin-mdr-crc
Project description:DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and identify a recommended phase 2 dose (RP2D). In addition, this study will also assess the pharmacokinetic (PK)/pharmacodynamic (PD) profiles and preliminary efficacy of DS-6051b.
| 2177400 | ecrin-mdr-crc
Project description:Cancer immunotherapy has demonstrated great promise with the checkpoint inhibitors being approved as the first-line therapy for some types of cancer, and engineered cytokines like Neo2/15 being evaluated in many studies. In this work, we designed Antibody Cytokine Chimera (ACC) scaffolding cytokine mimetics with full-length tumor-specific antibody. We characterized the pharmacokinetic (PK) and pharmacodynamic (PD) properties of first-generation ACC TA99-Neo2/15, which synergized with DLnano-vaccines in suppressing in vivo melanoma proliferation but caused significant systemic cytokine activation. A novel second-generation ACC TA99-HL2-KOA1, with retained IL-2Rβ/γ binding and attenuated but preserved IL-2Rα, caused significantly lower systemic cytokine activation and non-inferior protection in murine tumor studies. Transcriptomic experiment demonstrated up-regulation of Type I interferon responsive genes, particularly ISG15, in dendritic cells, macrophages and monocytes following TA99-HL2-KOA1 treatment. Characterization of additional ACCs in combination with cancer vaccines will likely be an important area of research for treating melanoma and other types of cancer.
2023-03-15 | GSE159553 | GEO
Project description:The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the maximum tolerated dose (MTD), and the recommended Phase 2 dose.
| 2742064 | ecrin-mdr-crc
Project description:This a model from the article:
Population-based analysis of methadone distribution and metabolism using an
age-dependent physiologically based pharmacokinetic model.
Yang F, Tong X, McCarver DG, Hines RN, Beard DA. J Pharmacokinet Pharmacodyn
2006 Aug;33(4):485-518 16758333
,
Abstract:
Limited pharmacokinetic (PK) and pharmacodynamic (PD) data are available to use
in methadone dosing recommendations in pediatric patients for either opioid
abstinence or analgesia. Considering the extreme inter-individual variability of
absorption and metabolism of methadone, population-based PK would be useful to
provide insight into the relationship between dose, blood concentrations, and
clinical effects of methadone. To address this need, an age-dependent
physiologically based pharmacokinetic (PBPK) model has been constructed to
systematically study methadone metabolism and PK. The model will facilitate the
design of cost-effective studies that will evaluate methadone PK and PD
relationships, and may be useful to guide methadone dosing in children. The PBPK
model, which includes whole-body multi-organ distribution, plasma protein
binding, metabolism, and clearance, is parameterized based on a database of
pediatric PK parameters and data collected from clinical experiments. The model
is further tailored and verified based on PK data from individual adults, then
scaled appropriately to apply to children aged 0-24 months. Based on measured
variability in CYP3A enzyme expression levels and plasma orosomucoid (ORM2)
concentrations, a Monte-Carlo-based simulation of methadone kinetics in a
pediatric population was performed. The simulation predicts extreme variability
in plasma concentrations and clearance kinetics for methadone in the pediatric
population, based on standard dosing protocols. In addition, it is shown that
when doses are designed for individuals based on prior protein expression
information, inter-individual variability in methadone kinetics may be greatly
reduced.
This model was taken from the CellML repository
and automatically converted to SBML.
The original model was:
Yang F, Tong X, McCarver DG, Hines RN, Beard DA. (2006) - version=1.0
The original CellML model was created by:
Catherine Lloyd
c.lloyd@auckland.ac.nz
The University of Auckland
This model originates from BioModels Database: A Database of Annotated Published Models (http://www.ebi.ac.uk/biomodels/). It is copyright (c) 2005-2011 The BioModels.net Team.
To the extent possible under law, all copyright and related or neighbouring rights to this encoded model have been dedicated to the public domain worldwide. Please refer to CC0 Public Domain Dedication
for more information.
In summary, you are entitled to use this encoded model in absolutely any manner you deem suitable, verbatim, or with modification, alone or embedded it in a larger context, redistribute it, commercially or not, in a restricted way or not..
To cite BioModels Database, please use: Li C, Donizelli M, Rodriguez N, Dharuri H, Endler L, Chelliah V, Li L, He E, Henry A, Stefan MI, Snoep JL, Hucka M, Le Novère N, Laibe C (2010) BioModels Database: An enhanced, curated and annotated resource for published quantitative kinetic models. BMC Syst Biol., 4:92.
2005-01-01 | MODEL1006230040 | BioModels
Project description:Demin2013 - PKPD behaviour - 5-Lipoxygenase
inhibitors
This model is described in the article:
Systems pharmacology models
can be used to understand complex
pharmacokinetic-pharmacodynamic behavior: an example using
5-lipoxygenase inhibitors.
Demin O, Karelina T, Svetlichniy D,
Metelkin E, Speshilov G, Demin O Jr, Fairman D, van der Graaf PH,
Agoram BM.
CPT Pharmacometrics Syst Pharmacol
2013; 2: e74
Abstract:
Zileuton, a 5-lipoxygenase (5LO) inhibitor, displays complex
pharmaokinetic (PK)-pharmacodynamic (PD) behavior. Available
clinical data indicate a lack of dose-bronchodilatory response
during initial treatment, with a dose response developing after
~1-2 weeks. We developed a quantitative systems pharmacology
(QSP) model to understand the mechanism behind this phenomenon.
The model described the release, maturation, and trafficking of
eosinophils into the airways, leukotriene synthesis by the 5LO
enzyme, leukotriene signaling and bronchodilation, and the PK
of zileuton. The model provided a plausible explanation for the
two-phase bronchodilatory effect of zileuton-the short-term
bronchodilation was due to leukotriene inhibition and the
long-term bronchodilation was due to inflammatory cell
infiltration blockade. The model also indicated that the
theoretical maximum bronchodilation of both 5LO inhibition and
leukotriene receptor blockade is likely similar. QSP modeling
provided interesting insights into the effects of leukotriene
modulation.CPT: Pharmacometrics & Systems Pharmacology
(2013) 2, e74; doi:10.1038/psp.2013.49; advance online
publication 11 September 2013.
This model is hosted on
BioModels Database
and identified by:
BIOMD0000000490.
To cite BioModels Database, please use:
BioModels Database:
An enhanced, curated and annotated resource for published
quantitative kinetic models.
To the extent possible under law, all copyright and related or
neighbouring rights to this encoded model have been dedicated to
the public domain worldwide. Please refer to
CC0
Public Domain Dedication for more information.
2013-10-04 | BIOMD0000000490 | BioModels
Project description:In recent years, histone deacetylase inhibitors (HDACi) have garnered considerable interest for the treatment of adult and pediatric malignant brain tumors. However, owing to their broad-spectrum nature and inability to effectively penetrate the blood-brain barrier, HDACi have failed to provide significant clinical benefit to glioblastoma (GBM) patients to date. Moreover, global inhibition of HDACs results in widespread toxicity, highlighting the need for selective isoform targeting. While no isoform-specific HDACi are currently available, the second-generation hydroxamic acid-based HDACi quisinostat possesses sub-nanomolar specificity for class I HDAC isoforms, particularly HDAC1 and 2. Recently, we demonstrated that HDAC1 is the essential HDAC in GBM. Here, we panalyzed the neuro-pharmacokinetic, pharmacodynamic and radiation-sensitizing properties of quisinostat in preclinical models of GBM. We found that quisinostat is a well-tolerated and brain-penetrant molecule that significantly extended survival when administered in combination with radiation in vivo. The pharmacokinetic-pharmacodynamic-efficacy relationship was established by correlating free drug concentrations and evidence of target modulation in the brain with survival benefit. Together, these data provide a strong rationale for clinical development of quisinostat as a radiosensitizer for the treatment of GBM.
2023-11-23 | GSE241227 | GEO
Project description:This first-in-human (FIH) study evaluated RO7122290, a novel, bispecific fusion protein carrying a split trimeric 4-1BB (CD137) ligand and a fibroblast activation protein-α (FAP) binding site that effectively co-stimulates T cells for improved tumor cell killing in FAP-expressing tumors. Patients with advanced and/or metastatic solid tumors received escalating weekly intravenous doses of RO7122290 as a single agent (n = 65) or in combination with 120mg fixed dose of the anti-PD-L1 antibody atezolizumab given every 3 weeks (n = 50), across a tested RO7122290 dose range of 5 to 2000 mg and 45 to 2000 mg, respectively. Three dose-limiting toxicities (DLTs) were reported, two at different RO7122290 single-agent dose levels (grade 3 febrile neutropenia, grade 3 cytokine release syndrome) and one for the combination (grade 3 pneumonitis). No maximum tolerated dose (MTD) was identified. The pharmacokinetic (PK) profile of RO7122290 was typical of target-mediated drug disposition. The observed modulation of proximal and distal pharmacodynamic (PD) biomarkers is consistent with the postulated immune mode of action (MoA). Treatment-induced PD changes included an increase of proliferating and activated T cells in peripheral blood both in the single agent and combination arm. Furthermore, we observed an increased infiltration of intratumoral CD8+ and Ki67+CD8+ T cells for both treatment regimens, accompanied with the up-modulation of T cell activation genes and gene-signatures. Eleven patients experienced a complete or partial response, from which six were confirmed immune checkpoint inhibitor (CPI)-naive patients. Our results support continued evaluation of RO7122290 in combination with atezolizumab and other immuno-oncology agents.
2022-11-16 | GSE212521 | GEO